By Counterforce Health Team in Vitrakvi (larotrectinib) —

How to Get Vitrakvi (Larotrectinib) Covered by Humana in New York: PA Requirements, Appeals, and External Review Guide

Answer Box: Getting Vitrakvi Covered by Humana in New York

Vitrakvi (larotrectinib) is covered on Humana's Medicare Advantage formulary but requires prior authorization. Your oncologist must submit documentation proving NTRK gene fusion positivity, metastatic/unresectable disease, and prior therapy history. If denied, you have 65 days to appeal internally, then 4 months to request external review through New York's Department of Financial Services. First step today: Have your oncologist gather your NTRK fusion test results and contact CenterWell Specialty Pharmacy to initiate the prior authorization process.

Table of Contents

  1. Plan Types & Coverage Implications
  2. Formulary Status & Tier Placement
  3. Prior Authorization Requirements
  4. Specialty Pharmacy Network
  5. Cost-Share Dynamics
  6. Submission Process
  7. Common Approval Patterns
  8. Appeals Process for New York
  9. External Review Through DFS
  10. FAQ

Plan Types & Coverage Implications

Humana operates primarily Medicare Advantage plans in New York, covering both Part C (medical) and Part D (prescription drug) benefits. Unlike traditional Medicare, these plans use utilization management tools like prior authorization and step therapy to control specialty drug costs.

Key differences for Vitrakvi coverage:

  • Medicare Advantage: Requires PA through Humana's internal process
  • Network restrictions: Must use Humana-contracted specialty pharmacies
  • Appeals rights: Both Medicare appeals and New York state external review available
Note: If you have traditional Medicare with a standalone Part D plan from Humana, the prior authorization process is similar but appeals follow Medicare Part D timelines.

Formulary Status & Tier Placement

Vitrakvi is included on Humana's 2024 Medicare Advantage formulary but sits in a high-cost specialty tier. According to Humana's drug formulary, the medication requires prior authorization for all coverage.

Coverage at a Glance

Requirement Status Details Source
Formulary Coverage ✓ Covered Listed on 2024 formulary Humana Drug List
Prior Authorization ✓ Required Mandatory for all requests PA Policy
Step Therapy Variable May require failed alternatives Plan-specific
Quantity Limits 30-day supply Initial fills limited Specialty network standard
Specialty Pharmacy ✓ Required CenterWell preferred Network Info

Prior Authorization Requirements

Humana's prior authorization for Vitrakvi demands comprehensive documentation proving medical necessity. The key is demonstrating that you have an NTRK gene fusion-positive solid tumor that meets FDA-approved indications.

Essential Documentation Checklist

✓ NTRK Gene Fusion Test Results:

  • FDA-approved diagnostic (NGS, FISH, or RT-PCR)
  • Laboratory report showing fusion positivity
  • Test date and performing lab identified
  • Fusion partner details when available

✓ Oncologic Diagnosis:

  • Pathology report confirming solid tumor
  • Staging documentation (metastatic/unresectable)
  • ICD-10 diagnosis codes

✓ Clinical History:

  • Prior systemic therapies attempted
  • Outcomes and reasons for discontinuation
  • Performance status (ECOG 0-2)
  • Treatment goals and monitoring plan

✓ Prescriber Credentials:

  • Board-certified oncologist required
  • Provider NPI and credentials on file

Clinician Corner: Medical Necessity Letter

Your oncologist's letter should address these key points:

  • Problem statement: NTRK fusion-positive solid tumor, metastatic/unresectable
  • Prior treatments: Specific agents tried, doses, duration, outcomes
  • Clinical rationale: Why Vitrakvi is necessary over alternatives
  • Guideline support: Reference to FDA labeling and NCCN guidelines
  • Monitoring plan: How response will be assessed

Specialty Pharmacy Network

Vitrakvi must be dispensed through Humana's specialty pharmacy network. The medication is not available at retail pharmacies due to its specialized handling requirements and manufacturer restrictions.

Primary Network Partner

CenterWell Specialty Pharmacy is Humana's preferred partner for Vitrakvi dispensing. Your prescriber should:

  1. Verify network status through Humana's provider portal
  2. Submit PA documentation directly to CenterWell
  3. Coordinate patient enrollment for specialty pharmacy services
  4. Arrange delivery logistics (typically 2-3 business days)
Tip: CenterWell offers patient support services including medication education, side effect management, and refill coordination. These services are included at no additional cost.

Cost-Share Dynamics

Vitrakvi's placement in Humana's specialty tier means significant cost-sharing, but several programs can help reduce out-of-pocket expenses:

Potential Cost-Reduction Options:

  • Manufacturer copay program: Bayer's TRAK Assist may reduce copays to $0 for eligible commercial patients
  • Medicare Extra Help: Low-income subsidy program for Part D costs
  • State pharmaceutical assistance: New York's EPIC program for Medicare beneficiaries
Important: Cost-sharing details vary by specific Humana plan. Check your Summary of Benefits or contact member services at the number on your ID card.

Submission Process

Step-by-Step: Fastest Path to Approval

1. Gather Documentation (Patient + Clinic)

  • Collect NTRK fusion test results
  • Compile treatment history records
  • Obtain current staging scans
  • Timeline: 1-2 days

2. Prescriber Submits PA (Clinic)

  • Complete prior authorization form
  • Include all supporting documentation
  • Submit via provider portal or fax
  • Timeline: Same day

3. Humana Reviews Request (Automated)

  • Initial screening for completeness
  • Clinical review by oncology pharmacist
  • Decision notification sent
  • Timeline: 1-3 business days

4. Pharmacy Coordination (CenterWell)

  • Prescription processing upon approval
  • Patient enrollment and education
  • Delivery scheduling
  • Timeline: 2-3 business days

Common Approval Patterns

Based on Humana's 3.5% Medicare Advantage PA denial rate (among the lowest of major insurers), most well-documented Vitrakvi requests are approved on first submission.

Common Denial Reasons & Fixes

Denial Reason How to Overturn Required Documentation
Missing NTRK test Submit molecular pathology report FDA-approved assay results
Insufficient prior therapy Document treatment history Detailed therapy timeline with outcomes
Non-specialist prescriber Transfer to oncologist Board-certified oncology provider
Resectable disease Provide staging documentation Imaging showing unresectable/metastatic disease

Appeals Process for New York

If Humana denies your Vitrakvi prior authorization, New York residents have robust appeal rights through both Medicare and state processes.

Internal Appeals Timeline

Medicare Advantage (Part C) Appeals:

  • Deadline: 65 days from denial notice
  • Standard timeline: 30 days for pre-service decisions
  • Expedited timeline: 72 hours for urgent cases
  • How to file: Humana member portal or phone

Part D Prescription Appeals:

  • Deadline: 65 days from denial notice
  • Standard timeline: 7 days for drug appeals
  • Expedited timeline: 24 hours for urgent requests
  • Required: Coverage determination form

Scripts & Templates

Patient Phone Script for Humana Appeals: "I'm calling to file an appeal for my denied Vitrakvi prescription. My member ID is [number]. The denial was for medical necessity, but my oncologist has documented that I have an NTRK fusion-positive tumor and have failed standard therapies. I need to file an expedited appeal because any delay in treatment could seriously harm my health."

External Review Through DFS

New York's external review process provides a final appeal option when Humana upholds its denial. This independent review is conducted by the New York Department of Financial Services (DFS) and is binding on the insurer.

New York External Review Process

Eligibility: Available after Humana's final adverse determination for denials based on:

  • Medical necessity
  • Experimental/investigational status
  • Coverage exclusions

Timeline: 4 months from Humana's final denial to file with DFS

Process:

  1. Submit DFS application with denial letters and clinical documentation
  2. Independent medical review by specialist in relevant field
  3. Binding decision typically within 30 days (72 hours if expedited)

Success rates: New York's external review program has historically overturned many specialty drug denials, particularly for rare disease treatments with strong clinical evidence.

Support Resources

Community Health Advocates (CHA):

  • Free counseling on insurance appeals
  • Helpline: 888-614-5400
  • Assistance with DFS external review filing

New York State Department of Financial Services:

When to Escalate

Consider escalating to external review when:

  • Humana denies despite complete NTRK fusion documentation
  • Clinical urgency exists (disease progression)
  • Similar cases have succeeded in New York's external review database
  • Your oncologist strongly supports medical necessity

FAQ

How long does Humana's prior authorization take for Vitrakvi in New York? Standard PA decisions are made within 1-3 business days. Expedited requests (for urgent clinical situations) are decided within 24 hours.

What if Vitrakvi isn't on my specific Humana formulary? You can request a formulary exception with your prescriber's support, demonstrating medical necessity over covered alternatives.

Can I get an expedited appeal if I'm already on Vitrakvi? Yes, if interrupting treatment would seriously jeopardize your health, you can request expedited review through both Humana and New York's external review process.

Does step therapy apply if I failed treatments outside New York? Prior therapy documentation from any location is typically accepted, but ensure your oncologist provides detailed records of treatments tried and outcomes.

What's the cost difference between CenterWell and other specialty pharmacies? Cost-sharing is typically the same across Humana's network, but CenterWell may offer additional patient support services at no extra charge.

How do I know if my NTRK test meets Humana's requirements? The test must be FDA-approved (such as FoundationOne CDx) and clearly document NTRK fusion positivity. Your oncologist can verify if your specific test meets criteria.

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. Our platform ingests denial letters, plan policies, and clinical notes to draft point-by-point rebuttals aligned to each payer's specific requirements, pulling the right citations and clinical facts to support coverage for medications like Vitrakvi.

Getting Vitrakvi covered by Humana requires patience and thorough documentation, but New York residents benefit from some of the nation's strongest appeal rights. When you work with experienced oncology providers and utilize available support resources, most medically appropriate requests ultimately succeed. For additional guidance on navigating complex prior authorizations and appeals, Counterforce Health offers specialized support for turning denials into approvals.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual circumstances and plan specifics. Always consult with your healthcare provider and insurance plan directly for guidance on your specific situation. Coverage policies and procedures may change; verify current information with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.